JPH08501563A - グループbストレプトコッカス・タイプ▲ii▼およびタイプ▲v▼多糖−蛋白質接合ワクチン - Google Patents
グループbストレプトコッカス・タイプ▲ii▼およびタイプ▲v▼多糖−蛋白質接合ワクチンInfo
- Publication number
- JPH08501563A JPH08501563A JP6508441A JP50844194A JPH08501563A JP H08501563 A JPH08501563 A JP H08501563A JP 6508441 A JP6508441 A JP 6508441A JP 50844194 A JP50844194 A JP 50844194A JP H08501563 A JPH08501563 A JP H08501563A
- Authority
- JP
- Japan
- Prior art keywords
- type
- polysaccharide
- vaccine
- group
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.グループBストレプトコッカス・タイプIIまたはタイプVバクテリアから誘 導される群から選ばれる莢膜多糖と、蛋白質成分を含み、この多糖成分のシアル 酸残基で終わる2以上の側鎖が、第二アミン結合で蛋白質にそれぞれリンクされ ており、上記多糖の分子量が5000ダルトン以上であることを特徴とする抗原 接合分子。 2.各多糖の末端シアル酸残基の5〜50%が、蛋白質にリンクされるのに有用 である請求項1の接合分子。 3.各多糖の末端シアル酸残基の5〜25%が、蛋白質にリンクされるのに有用 である請求項2の接合分子。 4.各多糖の末端シアル酸残基の5〜10%が、蛋白質にリンクされるのに有用 である請求項3の接合分子。 5.上記多糖がGBSタイプIIであり、各多糖の末端シアル酸残基の7%が、蛋 白質にリンクされるのに有用である請求項4の接合分子。 6.上記抗原接合分子が0.2ミクロンのフィルターを通して濾過減菌されうる 請求項1の接合分子。 7.上記多糖成分が約5,000〜1,000,000ダルトンの分子量を有す る請求項1の接合分子。 8.上記多糖成分が約50,000〜500,000ダルトンの分子量を有する 請求項7の接合分子。 9.上記多糖がGBSタイプVであり、各多糖の末端シアル酸残基の約25%が 、蛋白質にリンクされるのに有用である請求項1の接合分子。 10.上記多糖成分が約100,000〜300,000ダルトンの分子量を有 する請求項8の接合分子。 11.上記多糖成分が約200,000ダルトンの分子量を有する請求項9の接 合分子。 12.上記蛋白質が破傷風トキソイド、ジフテリアトキソイド及びCRM(交差 反応物質)197からなる群から選ばれる請求項1の接合分子。 13.グループBストレプトコッカス・タイプIIまたはタイプVバクテリアの莢 膜多糖と蛋白質の接合分子を製造する方法であって、 (a)グループBのストレプトコッカス・タイプIIの莢膜多糖を、該多糖の骨 格にリンクした2以上の末端シアル酸残基にアルデヒド基を導入するに充分なだ け、過ヨウ素酸化し、 (b)酸化されたグループBのストレプトコッカス・タイプIIの莢膜多糖を、 還元的アミノ化によって、蛋白質と連結させ、莢膜多糖と蛋白質の間に第二アミ ン結合を生じさせることを特徴とする方法。 14.各多糖のシアル酸残基の約5〜50%が酸化されて、蛋白質に連結可能な アルデヒド群を形成する請求項13の方法。 15.各多糖のシアル酸残基の約5〜25%が酸化されて、蛋白質に連結可能な アルデヒド群を形成する請求項14の方法。 16.各多糖のシアル酸残基の約5〜10%が酸化されて、蛋白質に連結可能な アルデヒド群を形成する請求項15の方法。 17.上記多糖がGBSタイプIIであり、各多糖のシアル酸残基の7%が酸化さ れて、蛋白質に連結可能なアルデヒド群を形成する請求項16の方法。 18.各多糖のシアル酸残基の約5〜50%が蛋白質に共有結合的にリンクされ る請求項13の方法。 19.各多糖のシアル酸残基の約5〜25%が蛋白質に共有結合的にリンクされ る請求項18の方法。 20.各多糖のシアル酸残基の約5〜10%が蛋白質に共役結合的にリンクされ る請求項19の方法。 21.上記多糖がGBSタイプIIであり、各多糖のシアル酸残基の約5%が共有 結合的に蛋白質にリンクされる請求項19の方法。 22.上記多糖がGBSタイプVであり、各多糖の末端シアル酸残基の約25% が蛋白質にリンクされる請求項13の方法。 23.請求項13の方法により製造される接合分子。 24.請求項1の接合分子を含むワクチン。 25.請求項1の接合分子と、グループBのストレプトコッカス・タイプII以外 の病原性物質に対する抗体の産出を引き出しうる他の免疫原性分子の少なくとも 一種を含む多価ワクチン。 26.上記他の免疫原性分子が、グループBのストレプトコッカス・タイプIa 、Ib、II、III、IVおよびV、ヘモフィラス・インフルエンザ・タイプb及びE . コリ・タイプK1からなる群から選ばれる病原体に対する抗体の産出を引き出し うるものである請求項25の多価ワクチン。 27.上記他の免疫原性分子が、グループBのストレプトコッカス・タイプIa 、Ib、II、III、ヘモフィラス・インフルエンザ・タイプb及びE.コリ・タイ プK1からなる群から選ばれる病原体に対する抗体の産出を引き出しうるもので ある請求項26の多価ワクチン。 28.上記他の免疫原性分子が、グループBのストレプトコッカス・タイプIa 、Ib、II、III及びE.コリ・タイプK1からなる群から選ばれる病原体に対す る抗体の産出を引き出しうるものである請求項27の多価ワクチン。 29.上記他の免疫原性分子が、グループBのストレプトコッカス・タイプIa 、Ib、II、IIIからなる群から選ばれる病原体に対する抗体の産出を引き出しう るものである請求項28の多価ワクチン。 30.請求項1の接合分子を、免疫原性量、女性に投薬し、十分量のワクチンの 投薬の前又は後に身籠った胎児に移行しうる抗体を産出させ、誕生時の新生児に おける感染症に対する保護を生じさせることを特徴とする新生児を免疫性にする 方法。 31.上記ワクチンが、妊娠前に投薬される請求項30の方法。 32.上記ワクチンが約10歳から50歳の間の女性に投薬される請求項30の 方法。 33.上記ワクチンが、妊娠期間中に投薬される請求項30の方法。 34.請求項1の接合分子を含むワクチンを人に免疫原性量で投薬する人を免疫 性にする方法。 35.請求項1の接合分子を含むワクチンを、グループBのストレプトコッカス ・タイプII又はタイプVにより感染される危険性のある人に免疫原性量で投薬す る成人を免疫性にする方法。 36.上記ワクチンを免疫系が抑制される人に投薬する請求項35の方法。 37.免疫抑制が癌又は糖尿病からなる群から選ばれる病気によるものである請 求項36の方法。 38.上記ワクチンが、薬学的に許容される担体で、投薬される請求項37の方 法。 39.請求項1の接合分子を含むワクチンを、免疫原性量、乳牛に投薬すること を特徴とする牛類の乳腺炎に対して乳牛類を免疫性にする方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94997092A | 1992-09-24 | 1992-09-24 | |
US07/949,970 | 1992-09-24 | ||
US12555693A | 1993-09-23 | 1993-09-23 | |
US08/125,556 | 1993-09-23 | ||
PCT/US1993/009056 WO1994006467A1 (en) | 1992-09-24 | 1993-09-24 | Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005196902A Division JP4308174B2 (ja) | 1992-09-24 | 2005-07-05 | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08501563A true JPH08501563A (ja) | 1996-02-20 |
JP4163251B2 JP4163251B2 (ja) | 2008-10-08 |
Family
ID=26823688
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50844194A Expired - Fee Related JP4163251B2 (ja) | 1992-09-24 | 1993-09-24 | グループbストレプトコッカス・タイプ▲ii▼およびタイプ▲v▼多糖−蛋白質接合ワクチン |
JP2005196902A Expired - Fee Related JP4308174B2 (ja) | 1992-09-24 | 2005-07-05 | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン |
JP2009055767A Pending JP2009132727A (ja) | 1992-09-24 | 2009-03-09 | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005196902A Expired - Fee Related JP4308174B2 (ja) | 1992-09-24 | 2005-07-05 | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン |
JP2009055767A Pending JP2009132727A (ja) | 1992-09-24 | 2009-03-09 | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン |
Country Status (16)
Country | Link |
---|---|
US (2) | US5795580A (ja) |
EP (1) | EP0667787B1 (ja) |
JP (3) | JP4163251B2 (ja) |
KR (1) | KR100293017B1 (ja) |
AT (1) | ATE203167T1 (ja) |
AU (1) | AU690525B2 (ja) |
CA (1) | CA2145397C (ja) |
DE (1) | DE69330464T2 (ja) |
DK (1) | DK0667787T3 (ja) |
ES (1) | ES2160601T3 (ja) |
FI (1) | FI110993B (ja) |
GR (1) | GR3036928T3 (ja) |
IL (1) | IL107103A (ja) |
NO (2) | NO319569B1 (ja) |
NZ (2) | NZ248766A (ja) |
PT (1) | PT667787E (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008518953A (ja) * | 2004-11-01 | 2008-06-05 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 連鎖球菌修飾多糖類およびそれらの使用法 |
JP2008532930A (ja) * | 2005-02-01 | 2008-08-21 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 連鎖球菌性莢膜糖の複合 |
JP2013538228A (ja) * | 2010-09-16 | 2013-10-10 | ノバルティス アーゲー | 免疫原性組成物 |
JP2018514571A (ja) * | 2015-05-04 | 2018-06-07 | ファイザー・インク | B群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69719677T2 (de) * | 1996-11-18 | 2003-09-18 | Japan Storage Battery Co Ltd | Positivelektrode für Lithiumbatterie und Lithiumbatterie |
EP1053021B1 (en) * | 1998-02-05 | 2009-01-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
WO2002012294A2 (en) | 2000-08-08 | 2002-02-14 | St. Jude Children's Research Hospital | Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof |
SV2003000753A (es) * | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
WO2003015815A1 (en) * | 2001-08-21 | 2003-02-27 | The Brigham And Women's Hospital, Inc. | Improved conjugate vaccines |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
WO2004089407A2 (en) | 2003-03-31 | 2004-10-21 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
US7972608B2 (en) * | 2003-06-23 | 2011-07-05 | Baxter International Inc. | Carrier proteins for vaccines |
US8206726B2 (en) * | 2006-02-06 | 2012-06-26 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
WO2013009945A1 (en) | 2011-07-12 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
AR092897A1 (es) | 2012-10-03 | 2015-05-06 | Novartis Ag | Composiciones inmunogenicas |
CN108135167B (zh) | 2015-08-19 | 2021-07-09 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
US20220211859A1 (en) * | 2019-05-10 | 2022-07-07 | Glaxosmithkline Biologicals Sa | Conjugate production |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
US4207414A (en) * | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
IE51174B1 (en) * | 1980-04-14 | 1986-10-29 | Merck & Co Inc | Group b streptococcal capsular polysaccharides |
US4438261A (en) * | 1980-05-19 | 1984-03-20 | Riker Laboratories, Inc. | Anticoagulant substance |
US4367222A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immune globulin specific to Group B streptococci |
US4367221A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immunization against Group B streptococci |
US4367223A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Vaccine against Group B streptococci |
US4356263A (en) * | 1980-06-09 | 1982-10-26 | President And Fellows Of Harvard College | Method of making a polysaccharide vaccine |
US4284537A (en) * | 1980-07-03 | 1981-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate of streptococcal M protein peptide vaccine |
US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
US4757134A (en) * | 1982-12-02 | 1988-07-12 | The Rockefeller University | IgA binding protein |
DE3584866D1 (de) * | 1984-09-12 | 1992-01-23 | Chiron Corp | Hybridpartikel-immunogene. |
FR2581877B1 (fr) * | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
EP0302887B1 (en) * | 1986-04-16 | 1994-06-22 | The Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines, and methods of manufacture |
US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
NZ225372A (en) * | 1987-07-17 | 1991-04-26 | Xoma Corp | Immunotoxin composition comprising purified ricin-a-chain species |
IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
RO111416B1 (ro) * | 1989-12-14 | 1996-10-31 | Ca Nat Research Council | Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare |
FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
-
1993
- 1993-09-24 PT PT93922357T patent/PT667787E/pt unknown
- 1993-09-24 EP EP93922357A patent/EP0667787B1/en not_active Expired - Lifetime
- 1993-09-24 NZ NZ248766A patent/NZ248766A/en not_active IP Right Cessation
- 1993-09-24 IL IL10710393A patent/IL107103A/en not_active IP Right Cessation
- 1993-09-24 DK DK93922357T patent/DK0667787T3/da active
- 1993-09-24 AU AU51378/93A patent/AU690525B2/en not_active Ceased
- 1993-09-24 AT AT93922357T patent/ATE203167T1/de not_active IP Right Cessation
- 1993-09-24 NZ NZ299249A patent/NZ299249A/xx not_active IP Right Cessation
- 1993-09-24 DE DE69330464T patent/DE69330464T2/de not_active Expired - Fee Related
- 1993-09-24 KR KR1019950701137A patent/KR100293017B1/ko not_active IP Right Cessation
- 1993-09-24 ES ES93922357T patent/ES2160601T3/es not_active Expired - Lifetime
- 1993-09-24 CA CA002145397A patent/CA2145397C/en not_active Expired - Fee Related
- 1993-09-24 JP JP50844194A patent/JP4163251B2/ja not_active Expired - Fee Related
-
1995
- 1995-03-23 NO NO19951109A patent/NO319569B1/no not_active IP Right Cessation
- 1995-03-24 FI FI951412A patent/FI110993B/fi active
- 1995-03-24 NO NO951152A patent/NO951152D0/no unknown
- 1995-06-07 US US08/483,647 patent/US5795580A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 US US09/023,526 patent/US5993825A/en not_active Expired - Fee Related
-
2001
- 2001-10-18 GR GR20010401795T patent/GR3036928T3/el not_active IP Right Cessation
-
2005
- 2005-07-05 JP JP2005196902A patent/JP4308174B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-09 JP JP2009055767A patent/JP2009132727A/ja active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008518953A (ja) * | 2004-11-01 | 2008-06-05 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 連鎖球菌修飾多糖類およびそれらの使用法 |
JP2008532930A (ja) * | 2005-02-01 | 2008-08-21 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 連鎖球菌性莢膜糖の複合 |
JP2013538228A (ja) * | 2010-09-16 | 2013-10-10 | ノバルティス アーゲー | 免疫原性組成物 |
JP2018514571A (ja) * | 2015-05-04 | 2018-06-07 | ファイザー・インク | B群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
JP2022008445A (ja) * | 2015-05-04 | 2022-01-13 | ファイザー・インク | B群レンサ球菌多糖-タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
KR950703361A (ko) | 1995-09-20 |
CA2145397A1 (en) | 1994-03-31 |
US5795580A (en) | 1998-08-18 |
JP2009132727A (ja) | 2009-06-18 |
NZ299249A (en) | 2000-08-25 |
FI951412A (fi) | 1995-05-24 |
DK0667787T3 (da) | 2001-10-29 |
EP0667787B1 (en) | 2001-07-18 |
AU690525B2 (en) | 1998-04-30 |
IL107103A0 (en) | 1994-08-26 |
DE69330464D1 (en) | 2001-08-23 |
FI951412A0 (fi) | 1995-03-24 |
ATE203167T1 (de) | 2001-08-15 |
JP4308174B2 (ja) | 2009-08-05 |
NO951152D0 (no) | 1995-03-24 |
JP4163251B2 (ja) | 2008-10-08 |
EP0667787A1 (en) | 1995-08-23 |
FI110993B (fi) | 2003-05-15 |
IL107103A (en) | 2001-03-19 |
NO319569B1 (no) | 2005-08-29 |
AU5137893A (en) | 1994-04-12 |
NO951109D0 (no) | 1995-03-23 |
US5993825A (en) | 1999-11-30 |
GR3036928T3 (en) | 2002-01-31 |
CA2145397C (en) | 2007-10-30 |
PT667787E (pt) | 2001-10-31 |
KR100293017B1 (ko) | 2001-09-17 |
DE69330464T2 (de) | 2001-11-08 |
JP2005306884A (ja) | 2005-11-04 |
NO951109L (no) | 1995-05-22 |
ES2160601T3 (es) | 2001-11-16 |
NZ248766A (en) | 1996-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4308174B2 (ja) | グループbストレプトコッカス・タイプiiおよびタイプv多糖−蛋白質接合ワクチン | |
US7332173B2 (en) | Group A streptococcal polysaccharide immunogenic compositions and methods | |
JP2736248B2 (ja) | 莢膜ポリマーフラグメントの製造方法 | |
Paoletti et al. | Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine | |
Paoletti et al. | Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine | |
US5955079A (en) | Dual carrier immunogenic construct | |
EP0831898B1 (en) | Modified meningococcal polysaccharide conjugate vaccines | |
US5843461A (en) | Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines | |
NZ239643A (en) | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. | |
EA006602B1 (ru) | Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций | |
WO1994005325A1 (en) | Vaccines against group c neisseria meningitidis | |
US4762713A (en) | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers | |
Lett et al. | Immunogenicity of polysaccharides conjugated to peptides containing T-and B-cell epitopes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050810 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050929 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20061221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080606 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080724 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110801 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |